menu search

Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™

Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™
Activities Focused on Xequel’s Ophthalmic Solution Containing aCT1 Peptide, Being Developed for the Treatment of Persistent Corneal Epithelial Defect and Recurrent Corneal Erosions SAN DIEGO and GAINESVILLE, Ga., May 08, 2023 (GLOBE NEWSWIRE) — Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO), today announced that it has been selected […] The post Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinic... Read More
Posted: May 8 2023, 11:00
Author Name: forextv
Views: 102093

Search within

Pages Search Results: